Sugar Maple Asset Management LLC Invests $373,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Sugar Maple Asset Management LLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, Holdings Channel reports. The firm acquired 7,800 shares of the biopharmaceutical company’s stock, valued at approximately $373,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Geode Capital Management LLC grew its stake in Halozyme Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after buying an additional 30,901 shares during the last quarter. Congress Asset Management Co. boosted its holdings in Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares during the period. Handelsbanken Fonder AB boosted its holdings in Halozyme Therapeutics by 76.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares during the period. Finally, Boston Trust Walden Corp boosted its holdings in Halozyme Therapeutics by 54.0% in the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock valued at $39,073,000 after purchasing an additional 239,321 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $54.80 on Tuesday. The company has a market cap of $6.97 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.42 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a 50 day simple moving average of $49.50 and a 200 day simple moving average of $54.14. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53.

Analyst Ratings Changes

A number of analysts have issued reports on HALO shares. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.